+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cystoscope Market - Forecasts from 2021 to 2026

  • PDF Icon


  • 111 Pages
  • July 2021
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 5397955
The global cystoscope market is expected to grow at a compound annual growth rate of 4.43% over the forecast period to reach a market size of US$791.791 million in 2026 from US$584.636 million in 2019. A cystoscope is a thin, telescope-like tube with a light and tiny camera attached instrument used to perform a cystoscopy, also known as cystourethroscopy, that allows a physician to examine and treat the lower urinary tract (urethra, prostate, bladder neck, and bladder). The cystoscope is inserted into the bladder through the urethra for the evaluation, treatment, or diagnoses of the conditions such as Bladder cancer, haematuria, frequent urinary tract infections (UTIs), Urinary blockage, Urinary stones, etc. making cystoscopy procedures one of the most commonly performed procedures in the urology office settings. Major companies have been providing novel and advanced solutions for their customers. For instance, Ambu, one of the largest suppliers of innovative and advanced single-use endoscopes, would be providing solutions for urology, in the coming years. The company had announced that it would launch a novel single-use, sterile, and high-resolution cystoscope in the year 2022. The company have also stated that they would launch a novel and single-use digital flexible ureteroscope in the year 2022. These trends and developments are expected to play a major role in the market growth, during the forecast period.

Rising incidences of urinary tract diseases boost the market.

The growth in the global cystoscope market may be attributed to the rising prevalence of urinary tract diseases globally. As per the data by the National Kidney Foundation, there are approximately 10 million doctor visits for urinary tract infections in the US. Similar rising incidences of other diseases such as prostate cancer, stones, bladder cancer, etc. will also boost the market during the given time frame. As per Cancer Research UK, prostate cancer is the most common cancer in men with around 47,700 new prostate cancer cases in the UK every year. However, complications such as infections, bleeding, and swollen urethra that may arise during cystoscopy procedures might restrain the growth of the market during the forecast period. According to a journal published in the United States National Library of Medicine National Institutes of Health, urinary tract infections are one of the most common infections, with an average lifetime incidence of 50-60% in most adult women. Urinary tract infections are some of the most common infections in the United States. The prevalence in women over 65 years is around 20%, compared with around 11% of the overall population. Moreover, there are around 258,000 cases of pyelonephritis in the United States, per year, with a higher and bigger frequency among females. In women, who are aged between 18-49 years, the total approximate incidence of pyelonephritis is around 28/10,000. These trends are expected to accelerate the demand for novel cystoscope devices and applications, in the coming years.

Asia Pacific to have a major share.

The market is expected to surge in the region due to the rising cases of urinary infections and prostate cancer. In India, according to the Indian Council of Medical Research, the incidence rate of prostate cancer in the country had been around 9-10/100,000 population, which is comparatively higher as compared to countries in Asia and Africa. In China, according to the National Cancer Registration Institute, prostate cancer has been the most common tumor in the male urinary system since the year 2008. These trends are expected to accelerate the demand for novel and advanced cystoscope products and systems.

Latest Developments.

In May 2021, UroViu Corporation, one of the major developers of a suite of self-contained, portable, and versatile single-use cystoscopy solutions, had announced that they had received a clearance from the United States of Food and Drug Administration to market and launch its third device, known as Uro-G. The novel product had been a single-use cystoscope with a detectable tip that allows physicians to perform diagnostic and interventional urologic procedures in their clinics, at any time, and in any room. This development is expected to have a positive impact on the market, in the coming years.

In May 2021, KARL STORZ Endoscopy America Inc., one of the key players in the market, announced the launch of its novel PDD Blue Light Flexible Video Cystoscopy System for improved detection of non-muscle invasive bladder cancer. The company had stated that the novel indications would surge the treatment of innovative therapy, across the United States.

In April 2021, Ambu Inc., one of the key players in the market, announced that it had received Health Canada clearance for the aScope 4 Crysto, the firm’s major advanced and innovative flexible cystoscope platform for urology. The novel product would allow urologists in Canada immediate access to a single-use cystoscope option for managing, treating, and diagnosing lower urinary disorders, such as bladder cancer, incontinence, and hematuria.

Market Segmentation:

By Type

  • Rigid Cystoscope
  • Flexible Cystoscope

By Applications

  • Urology
  • Gynecology

By End-User

  • Hospitals
  • Ambulatory Surgical Centers

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Thailand
  • Taiwan
  • Indonesia
  • Others
Frequently Asked Questions about the Cystoscope Market

What is the estimated value of the Cystoscope Market?

The Cystoscope Market was estimated to be valued at $584.64 million in 2019.

What is the growth rate of the Cystoscope Market?

The growth rate of the Cystoscope Market is 4.4%, with an estimated value of $791.79 million by 2026.

What is the forecasted size of the Cystoscope Market?

The Cystoscope Market is estimated to be worth $791.79 million by 2026.

Who are the key companies in the Cystoscope Market?

Key companies in the Cystoscope Market include Stryker, PENTAX Medical, Olympus Medical Corporation, Richard Wolf GmbH, Karl Storz, NeoScope Inc., Coloplast Group, Cogentix Medical and Sass Wolf.

Table of Contents

1. Introduction
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
2.2. Assumptions
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Cystoscope Market Analysis, By Type
5.1. Introduction
5.2. Rigid Cystoscope
5.3. Flexible Cystoscope
6. Cystoscope Market Analysis, By Applications
6.1. Introduction
6.2. Urology
6.3. Gynecology
7. Cystoscope Market Analysis, By End-User
7.1. Introduction
7.2. Hospitals
7.3. Ambulatory Surgical Centers
8. Cystoscope Market Analysis, By Geography
8.1. Introduction
8.2. North America
8.2.1. United States
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. UK
8.4.2. France
8.4.3. Germany
8.4.4. Italy
8.4.5. Others
8.5. Middle East and Africa
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Thailand
8.6.5. Taiwan
8.6.6. Indonesia
8.6.7. Others
9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. Company Profiles
10.1. Stryker
10.2. PENTAX Medical
10.3. Olympus Medical Corporation
10.4. Richard Wolf GmbH
10.5. Karl Storz
10.6. NeoScope Inc.
10.7. Coloplast Group
10.8. Cogentix Medical
10.9. Henke-Sass Wolf
10.10. Advanced Health Care Resources

Companies Mentioned

  • Stryker
  • PENTAX Medical
  • Olympus Medical Corporation
  • Richard Wolf GmbH
  • Karl Storz
  • NeoScope Inc.
  • Coloplast Group
  • Cogentix Medical
  • Henke-Sass Wolf
  • Advanced Health Care Resources